Overview

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Status:
Terminated

Trial end date:
2024-02-28

Target enrollment:

Participant gender:

Summary

This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.

Phase:

Phase 2

Details

Lead Sponsor:

Alexza Pharmaceuticals, Inc.

Collaborators:

DSG
ISS, Inc.
Peachtree BioResearch Solutions

Treatments:

Apomorphine